Migraine Treatment in ED
| Status: | Recruiting |
|---|---|
| Conditions: | Migraine Headaches |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 12/8/2017 |
| Start Date: | December 2015 |
| End Date: | December 2018 |
| Contact: | Ada Rubin |
| Email: | rubina07@nyumc.org |
Evaluation of a Behavioral Program for Migraineurs in the Emergency Department.
Randomized pilot feasibility study evaluating the impact of introducing behavioral treatment
for migraine in the Emergency Department (ED) and prescribing migraine preventive medications
in the ED. The study will examine the effect of these treatments, both individually and in
combination, on pain severity and headache-related disability. This study is designed to
examine the feasibility of comparing four interventions for ED patients presenting with
migraine. Group 1: Starting topiramate; Group 2: Doing a brief behavioral intervention; Group
3: Treating with combination therapy of topiramate and behavioral intervention; and Group 4:
Standard of Care.
for migraine in the Emergency Department (ED) and prescribing migraine preventive medications
in the ED. The study will examine the effect of these treatments, both individually and in
combination, on pain severity and headache-related disability. This study is designed to
examine the feasibility of comparing four interventions for ED patients presenting with
migraine. Group 1: Starting topiramate; Group 2: Doing a brief behavioral intervention; Group
3: Treating with combination therapy of topiramate and behavioral intervention; and Group 4:
Standard of Care.
Inclusion Criteria:
- age 18 years to 65 years of age
- primary diagnosis of migraine based on the International Classification of headache
disorders 3 beta criteria
- having a migraine 3 or more days/month.
Exclusion Criteria:
- Cognitive Behavioral Therapy (CBT), biofeedback or other relaxation therapy in the
past year
- being on medication used for migraine prevention (topiramate, propranolol, valproic
acid, amitriptyline/nortriptyline/imipramine/desipramine, botulinum toxin, a SNRI,
angiotensin-converting enzyme inhibitors (ACE-I) or ARB)
- cognitive deficit or other physical problem with the potential to interfere with
behavioral therapy
- substance or alcohol abuse as determined by self-report or prior documentation in the
medical record.
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Mia Ninen, M.D.
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
